Brokerage firm Jefferies Maintains its rating on Aquinox Pharmaceuticals Inc(NASDAQ:AQXP). In a research note issued to the investors, the brokerage major Raises the price-target to $9.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Aug 5, 2016.
Aquinox Pharmaceuticals Inc (AQXP) shares turned negative on Wednesdays trading session with the shares closing down -0.32 points or -3.43% at a volume of 2,05,647. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $9.36. The peak price level was also seen at $9.36 while the days lowest was $8.8. Finally the shares closed at $9. The 52-week high of the shares is $24.5 while the 52-week low is $6.0144. According to the latest information available, the market cap of the company is $155 M.
Aquinox Pharmaceuticals Inc(AQXP) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-0.63. Analysts had estimated an EPS of $-0.41.
Several Insider Transactions has been reported to the SEC. On Aug 26, 2015, David Chilton Mitchell (VP Global Regulatory & Quality) purchased 3,575 shares at $17.81 per share price.Also, On Aug 14, 2015, Lloyd Mackenzie (VP Technical Operations) sold 35,887 shares at $18.67 per share price.On Aug 14, 2015, Kamran Alam (CFO, Vice President Finance) sold 29,079 shares at $18.67 per share price, according to the Form-4 filing with the securities and exchange commission.
Aquinox Pharmaceuticals Inc. formerly Aquinox Pharmaceuticals (USA) Inc. is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals (Canada) Inc. is a wholly owned subsidiary of the Company. The primary focus of the Company is anti-inflammatory product candidates targeting SHIP1 which is a regulator of a cellular signaling pathway in immune cells known as the PI3K pathway. Its lead product candidate AQX-1125 is a small molecule activator of SHIP1 suitable for oral once daily dosing. The Company has completed multiple preclinical studies and clinical trials with AQX-1125 it is advancing through Phase II development in several initial indications. The Company operates in Vancouver British Columbia Canada.